Hepatocyte growth factor: Mesenchymal signal for epithelial homeostasis  by Kopp, Jeffrey B.
EDITORIAL
Hepatocyte growth factor: Mesenchymal signal for epithelial
homeostasis
Hepatocyte growth factor (HGF) was originally purified
from plasma based on its ability to stimulate mitogenesis of
hepatocytes. PreproHGF is produced as a 728 residue
polypeptide and following proteolytic processing, is se-
creted from cells as peptide with apparent molecular mass
of 92 kDa. Following tissue injury, HGF is proteolytically
cleaved to an active, disulfide-linked heterodimer consist-
ing of a 4-kringle-containing, 69 kDa alpha chain and a 32
to 34 kDa beta chain [1]. HGF is now recognized to have a
wide range of roles, contributing to embryonic morphogen-
esis, tumor progression, and tissue regeneration. Mice
bearing a null mutation in the HGF gene manifest embry-
onic lethality due to severe liver and placenta defects.
Somewhat surprisingly, kidney development is normal, at
least to embryonic days 13.5–15.5 when lethality occurs [2].
The pleiotrophic effects of HGF can perhaps best be
summarized as a complex message that is sent from the
mesenchyme to the epithelium and endothelium. HGF is
produced by fibroblastic cells, including renal interstitial
cells, and by cultured mesangial cells [3]. HGF is mitogenic
for a broad range of epithelial cells and endothelial cells. Its
receptor is the proto-oncogene c-met, a heterodimeric
transmembrane tyrosine kinase. Clearly, this mesenchyme-
to-epithelium model represents an oversimplification, as
HGF may also alter the phenotype of mesangial cells,
shifting cell shape towards the bipolar and reducing focal
adhesions [4].
HGF has additional effects on cell morphology. An
alternative name, scatter factor, refers to the observation
that following exposure to HGF, epithelial and endothelial
cells shift from a cobblestone layer morphology and spread,
dissociate, and adopt a bipolar morphology. Exposure to
HGF causes MDCK tubular epithelial cells in monolayer
culture on gel matrices to reposition themselves so as to
form branching tubules [5]. This observation has led to a
productive line of inquiry into the role of HGF in branching
morphogenesis in development, although as pointed out
above the normal early kidney development in the HGF
knockout mouse suggests that HGF is not absolutely
required for ureteric bud branching.
Transforming growth factor-b (TGF-b) family members
and HGF are complementary mediators of paracrine and
endocrine systems that regulate epithelial homeostasis [6].
Both growth factors are secreted in latent forms, circulate
in significant quantities, are released from platelets, asso-
ciate with extracellular matrix components (collagen IV
and decorin for TGF-b, and heparin sulfate proteoglycans
for HGF), and are activated by proteases (plasmin for
TGF-b and urine plasminogen activator for HGF). TGF-b
and HGF have reciprocal effects on the epithelium. First,
TGF-b induces epithelium to mesenchyme conversion,
while HGF induces mesenchyme to epithelium conversion
[7]. Second, TGF-b prevents epithelial cells from entering
the cell cycle while HGF overcomes this effect, possibly by
preventing down-regulation of Cdk2 and Cdk4. Thus, the
balance between production and activation of TGF-b and
HGF may determine whether the epithelium remains in a
quiescent and mature state or shifts to a proliferative and
migratory state associated with development and tissue
repair.
Not surprisingly, HGF has been implicated in renal
tubular epithelial proliferation in vivo. Following unilateral
nephrectomy, experimental ischemia or HgCl2 administra-
tion, there are increased plasma levels of HGF and in-
creased expression of HGF mRNA, localized to renal
interstitial cells, which have been tentatively identified as
endothelial cells, fibroblasts, or macrophages [8, 9]. Admin-
istration of HGF to animals ameliorates renal injury in the
setting of toxic injury (cisplatin, tacrolimus, HgCl2, glyc-
erol) and ischemia-reperfusion [10, 11]. In accord with
these experimental data, urinary HGF levels are increased
following acute renal failure in patients, while HGF levels
remain normal in chronic renal disease [12].
HGF may induce or antagonize apoptosis, in a fashion
that is dependent on cell type and culture conditions.
Recently, for example, HGF has been shown to reduce
apoptosis in murine IMCD-3 cells exposed to cisplatin [13].
Apoptosis may result from the activation of two distinct
pathways: occupancy of TNF/Fas family receptors and
signaling through death domain proteins, and the balance
among Bcl-2 family members, which include anti-apoptotic
members (such as Bcl-2 and BAG-1) and pro-apoptotic
members (such as Bax). HGF receptor occupancy may
suppress apoptosis by interfering with Fas pathway signal-
ing or by direct association with the BAG-1 protein [14, 15].
In the current issue of Kidney International, Yo and
colleagues extend the evidence that HGF acts to prevent
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apoptosis in renal epithelial cells, using serum-deprivation
as the apoptotic signal [16]. They showed that rat NRK-52E
cells and porcine LLC-PKl cells express c-met mRNA and
proliferate in response to HGF. Following 96 hours of
incubation in serum free medium, most cells underwent
apoptosis, assessed morphologically by nuclear condensa-
tion. Treatment with HGF or vascular endothelial growth
factor (VEGF) or serum attenuated the rate of apoptosis.
When apoptosis was assessed by DNA fragmentation in an
ELISA format assay, the same trend was seen, although the
magnitude of the protection was substantially less. Trans-
fection with an HGF-expression plasmid had similar anti-
apoptotic effects, indicating that preproHGF could be
activated in this system and exert similar effects.
Growth factor withdrawal, as seen in cultured cells
deprived of serum, induces apoptosis through the Bcl-2
family pathway. In vivo, apoptosis in tubular epithelial cells
occurs via the TNF/Fas pathway in some settings (for
example, immunologic injury) and via the Bcl-2 family
pathway in other settings (such as ischemia-reperfusion).
Less is known about apoptotic pathways in the glomerular
epithelium. Nonetheless, it is quite plausible that HGF
might act in vivo on renal epithelial cells to prevent
apoptosis.
Yo and colleagues also found that co-culture of mesan-
gial cells with NRK-52E or LLC-PK1 cells stimulated
epithelial cell growth, and antibody to HGF abrogated this
effect. Based on these findings, the authors posit the
existence of a paracrine loop, in which mesangial HGF
drives epithelial cell proliferation and suppresses apoptosis.
This is an appealing model that makes sense in terms of
what we know about HGF signaling. The authors do not
explicitly address whether the target cells in this model are
glomerular epithelial cells, tubular epithelial cells, or both.
Importantly, both glomerular epithelial cells and tubular
epithelial cells express c-met, and as reviewed above, it
appears that HGF produced within the interstitium may
speed epithelial repair following tubular injury. Nonethe-
less, evidence that mesangial HGF plays a role in epithelial
function or, indeed, is up-regulated in experimental kidney
disease or human kidney disease remains to be developed.
In human glomerular disease, HGF protein is localized to
tubular epithelial cells and is absent from the glomerulus
[17], but attempts to localize expression using in situ
hybridization have not been reported. As for the possibility
that mesangial HGF might drive tubular epithelial cell
proliferation, there has been no evidence in experimental
acute renal failure that glomerular production of HGF is
enhanced. Further studies using in situ hybridization, par-
ticularly in glomerular diseases characterized by glomerular
epithelial cell proliferation such as crescentic glomerulone-
phritis and the collapsing variant of focal segmental glo-
merulosclerosis, may help to establish whether and under
what conditions mesangial cells produce HGF in vivo.
Nevertheless, the HGF paracrine loop hypothesis pre-
sented here provides a useful construct to direct future
investigations.
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